secwatch.observer — SEC 8-K summary
======================================

Issuer:     LB PHARMACEUTICALS INC (LBRX)
CIK:        0001691082
Form:       8-K
Filed at:   2026-05-12T20:21:01+00:00
Accession:  0001193125-26-219529
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LB Pharma Q1 net loss $19.1M; cash $365.6M; Phase 3 schizophrenia trial launched
--------------------------------------------------------------------------------

- Net loss of $19.1M in Q1 2026 vs $5.3M in Q1 2025; R&D expenses rose $11.2M to $14.6M.
- Cash, equivalents, and marketable securities totaled $365.6M as of March 31, 2026; runway into Q2 2029.
- Initiated pivotal Phase 3 NOVA-2 trial of LB-102 in acute schizophrenia; topline data H2 2027.
- Phase 2 ILLUMINATE-1 trial in bipolar depression started Jan 2026; topline expected Q1 2028.
- Completed $100M private placement in Feb 2026; Phase 2 in adjunctive MDD planned early 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1691082/000119312526219529/0001193125-26-219529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1691082/000119312526219529/d134118d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-219529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer